Corvus Pharmaceuticals raises $30.2M in registered direct offering with CEO participation

Corvus Pharmaceuticals, Inc.

Entered Securities Purchase Agreement on May 1, 2024 to issue ~13.5M shares and warrants at $1.7312 per combined unit
Net proceeds expected ~$30.2M; closing expected May 6, 2024
Common warrants exercisable at $3.50/share, expiring June 30, 2025
CEO and existing institutional investors participated in the offering
Proceeds to be used for working capital, R&D, and general corporate purposes

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Corvus Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein, including the companys chief executive officer and certain of the companys existing institutional investors, including investors affiliated with certain of the companys directors (collectively, the Investors ) valued at combined offering price of $1.7312 (effective 2024-05-01).

Action: entry
Agreement: equity purchase
Counterparty: the investors named therein, including the companys chief executive officer and certain of the companys existing institutional investors, including investors affiliated with certain of the companys directors (collectively, the Investors )
Value: combined offering price of $1.7312
Effective: 2024-05-01

Exact text from the filing

On May 1, 2024, Corvus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein, including the Company’s chief executive officer and certain of the Company’s existing institutional investors, including investors affiliated with certain of the Company’s directors (collectively, the “Investors”).

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-131920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.